Ignite Creation Date:
2024-05-06 @ 4:33 PM
Last Modification Date:
2024-10-26 @ 2:12 PM
Study NCT ID:
NCT05028751
Status:
TERMINATED
Last Update Posted:
2024-04-22
First Post:
2021-08-25
Brief Title:
A Study to Evaluate Lanraplenib LANRA in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia AML
Sponsor:
Kronos Bio
Organization:
Kronos Bio
Study Overview
Official Title:
A Phase 1b2 Study of the Safety Pharmacokinetics Pharmacodynamics and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib LANRA in Combination With the FLT3 Inhibitor Gilteritinib in Patients With FLT3-mutated Relapsed or Refractory AML
Status:
TERMINATED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Sponsor decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to evaluate the safety of lanraplenib LANRA in combination with the FMS-like tyrosine kinase 3 FLT3 inhibitor gilteritinib in participants with relapsed or refractory RR FLT3-mutated acute myeloid leukemia AML
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2022-001279-15 | EUDRACT_NUMBER | None | None |